title: Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study.
abstract: OBJECTIVE
  Mitotane treatment in adrenocortical carcinoma (ACC) results in unreliable measurement of serum total cortisol (TC) levels because of an elevation in corticosteroid-binding globulin (CBG).
  
  
  METHODS
  The use of a newly-developed serum-free cortisol (FC) assay was assessed to investigate the characteristics of a more valid measure of cortisol status.
  
  
  METHODS
  Sixty-two serum samples from patients with ACC treated with mitotane were studied. Different subgroups were studied according to mitotane levels (<14, 14-20 and >20 mg/dl), hydrocortisone replacement treatment, presence of Cushing's syndrome (CS) and adrenocorticotrophin (ACTH) levels.
  
  
  METHODS
  Serum FC was measured using a newly-developed assay, TC, CBG and plasma ACTH using conventional laboratory kits; TC-to-CBG (Free cortisol index, FCI, nmol/mg) and TC-to-FC (TFR) ratios were calculated.
  
  
  RESULTS
  CBG levels were elevated and positively correlated to mitotane levels. FC was positively related to TC and FCI in nearly all subgroups studied. Plasma ACTH was negatively related to parameters of cortisol levels in the total samples studied. In the 'target' subgroup with normal ACTH levels and mitotane levels 14-20 mg/dl, no correlation of plasma ACTH with any parameter studied was seen, and FC suggested over-replacement with hydrocortisone treatment in the subgroup with CS.
  
  
  CONCLUSIONS
  FC measurement may offer additional information in the follow-up of patients on mitotane, especially when there is a history of CS which invalidates the use of acute changes in plasma ACTH as a parameter of hydrocortisone replacement. These preliminary data suggest that it may prove useful as a biochemical marker when TC or FCI are invalidated by mitotane treatment or plasma ACTH is suppressed by hypercortisolaemia. Larger studies are needed to substantiate the clinical utility of FC measurement in specific groups of patients.
authors.affiliation: Department of Endocrinology, St Bartholomew's Hospital, London, UK.
authors.forename: Krystallenia I
authors.initials: KI
authors.lastname: Alexandraki
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Kaltsas
authors.forename: Carel W
authors.initials: CW
authors.lastname: le Roux
authors.forename: Martin
authors.initials: M
authors.lastname: Fassnacht
authors.forename: Sharon
authors.initials: S
authors.lastname: Ajodha
authors.forename: Mirjam
authors.initials: M
authors.lastname: Christ-Crain
authors.forename: Scott A
authors.initials: SA
authors.lastname: Akker
authors.forename: William M
authors.initials: WM
authors.lastname: Drake
authors.forename: Ray
authors.initials: R
authors.lastname: Edwards
authors.forename: Bruno
authors.initials: B
authors.lastname: Allolio
authors.forename: Ashley B
authors.initials: AB
authors.lastname: Grossman
mesh_terms: D000306:Adrenal Cortex Neoplasms / Q000097:blood* / Q000188:drug therapy; D018268:Adrenocortical Carcinoma / Q000097:blood* / Q000188:drug therapy; D000324:Adrenocorticotropic Hormone / Q000097:blood; D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood*; D008297:Male; D008875:Middle Aged; D008939:Mitotane / Q000627:therapeutic use*; D010865:Pilot Projects
chemical_list: D018931:Antineoplastic Agents, Hormonal; D008939:Mitotane; D000324:Adrenocorticotropic Hormone; D006854:Hydrocortisone